Cadila Healthcare Ltd has informed BSE that the Board of Directors of Cadila Healthcare Limited ('Company') at its meeting held on November 17, 2016, has considered and approved the Scheme of Arrangement between Cadila Healthcare Limited and Zydus Healthcare Limited and their respective shareholders and creditors ['Scheme'] under sections 391 to 394 of the Companies Act, 1956. Zydus Healthcare Limited is a wholly owned subsidiary of the Company. As per the Scheme, India Human Formulations Undertaking of the Company will be transferred to Zydus Healthcare Limited on a Slump Sale [Section 2(42C) of the Income-tax Act, 1961] basis for lump-sum cash consideration. Cadila Healthcare Ltd has informed BSE regarding the details of Voting results of Court Convened Meeting, under Regulation 44(3) of SEBI (LODR) Regulations, 2015 -Consideration and approval of scheme of arrangement between Cadila Healthcare Limited and Zydus Healthcare Limited and their respective shareholders and creditors (As per BSE Announcement dated on 01.04.2017)